EGF binding is quantitatively related to growth in node-positive breast cancer.

abstract：:We previously identified a positive transcriptional element identical to human Ha-ras response element (HRE) within the promoter of the rat Ha-ras gene. We further identified CArG binding factor A (CBF-A), a member of heterogeneous nuclear ribonuclear protein (hnRNP) gene family, as a trans-acting factor that binds th...

journal_title：Breast cancer research and treatment

authors： Mikheev AM,Inoue A,Jing L,Mikheeva SA,Li V,Leanderson T,Zarbl H

更新日期：2004-11-01 00:00:00

abstract：:Intraoperative radiotherapy with electrons (ELIOT) after conservative surgery for breast carcinoma was introduced at the IEO in 1999 as a research programme. The results on 1,822 patients treated from January 2000 to December 2008 are reported. Women with unicentric primary breast carcinoma of less than 2.5 cm in the ...

journal_title：Breast cancer research and treatment

authors： Veronesi U,Orecchia R,Luini A,Galimberti V,Zurrida S,Intra M,Veronesi P,Arnone P,Leonardi MC,Ciocca M,Lazzari R,Caldarella P,Rotmensz N,Sangalli C,Sances D,Maisonneuve P

更新日期：2010-11-01 00:00:00

abstract：:Cytochrome P450s are enzymes which catalyze Phase-I metabolism reactions; cytochrome P450 1A1 (CYP1A1) is a member of the CYP1 family and participates in the metabolism of a vast number of xenobiotics, as well as endogenous substrates. Four single nucleotide polymorphisms in CYP1A1 have been studied concerning their p...

journal_title：Breast cancer research and treatment

authors： Sergentanis TN,Economopoulos KP

更新日期：2010-07-01 00:00:00

abstract：PURPOSE:Although quality of life (QoL) improves over time for most breast cancer survivors (BCS), BCS may show different patterns of QoL. This study sought to identify distinct QoL trajectories among BCS and to examine characteristics associated with trajectory group membership. METHODS:BCS (N = 653) completed baselin...

journal_title：Breast cancer research and treatment

authors： Goyal NG,Levine BJ,Van Zee KJ,Naftalis E,Avis NE

更新日期：2018-05-01 00:00:00

abstract：:The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

journal_title：Breast cancer research and treatment

authors： Hastie T,Sleeper L,Tibshirani R

更新日期：1992-01-01 00:00:00

abstract：:In previous studies we demonstrated that rat mammary tumor (RMT) cells that are serially transplantable consist of cells that are independent of growth factors strictly required by normal rat mammary epithelial (RME) cells for growth in serum-free culture. The present studies were designed to determine the extent of t...

journal_title：Breast cancer research and treatment

authors： Ethier SP,Moorthy R

更新日期：1991-05-01 00:00:00

abstract：:Previously we have shown that exercising rats prior to administration of 50 mg NMU/kg (high dose) significantly decreased tumor multiplicity, but not incidence or latency. We hypothesized that the dose of NMU saturated the system such that the exercise intervention was overshadowed. Therefore, the purpose of this inve...

journal_title：Breast cancer research and treatment

authors： Whittal-Strange KS,Chadan S,Parkhouse WS

更新日期：1998-01-01 00:00:00

abstract：:This review will focus on the role of sphingosine and its phosphorylated derivative sphingosine-1-phosphate (SPP) in cell growth regulation and signal transduction. We will show that many of the effects attributed to sphingosine in quiescent Swiss 3T3 fibroblasts are mediated via its conversion to SPP. We propose that...

journal_title：Breast cancer research and treatment

authors： Spiegel S,Olivera A,Zhang H,Thompson EW,Su Y,Berger A

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Insertion of radiopaque markers is helpful for tumor localization in patients receiving neoadjuvant chemotherapy (NAC) followed by breast-conserving surgery (BCS). The aim of this retrospective study was to investigate the pathologic margin status in patients with single or double marker insertion. METHODS:We ...

journal_title：Breast cancer research and treatment

authors： Cha C,Lee J,Kim D,Park S,Bae SJ,Eun NL,Ahn SG,Son EJ,Jeong J

更新日期：2020-12-01 00:00:00

abstract：PURPOSE:Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. R...

journal_title：Breast cancer research and treatment

authors： Watanabe J,Saito M,Horimoto Y,Nakamoto S

更新日期：2020-05-01 00:00:00

abstract：:A human estrogen receptor (ER) cDNA probe was used to examine genomic DNA extracted from 59 primary invasive breast cancers. The tumors were also studied histopathologically, and their ER status was assessed by hormone-binding assay and immunohistochemical analysis. Southern blots of genomic DNA samples digested with ...

journal_title：Breast cancer research and treatment

authors： Parl FF,Cavener DR,Dupont WD

更新日期：1989-10-01 00:00:00

abstract：MAIN PURPOSE:Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carriers (BRCAwt) with breast cancer. RESEARCH QUESTION:The re...

journal_title：Breast cancer research and treatment

authors： Stenehjem DD,Telford C,Unni SK,Bauer H,Sainski A,Deka R,Schauerhamer MB,Ye X,Tak CR,Ma J,Dalvi TB,Gutierrez L,Kaye JA,Tyczynski JE,Brixner DI,Biskupiak JE

更新日期：2021-01-03 00:00:00

abstract：:Breast cancer is heavily influenced by the reproductive history of the individual. Pregnancy has a protective effect which is attributed to differences in the degree of differentiation of the breast. The purpose of this work was to determine whether the quantity and the type of parenchymal structures present in the hu...

journal_title：Breast cancer research and treatment

authors： Russo J,Rivera R,Russo IH

更新日期：1992-01-01 00:00:00

abstract：:The sub-nipple tissue (SNT) examination has been used by surgeons to preserve, or not, the nipple in nipple-sparing mastectomy. However, it is uncertain whether SNT evaluation can predict nipple involvement. The aim of this study was to evaluate the accuracy, sensitivity, specificity, PPV, and NPV of the intraoperativ...

journal_title：Breast cancer research and treatment

authors： Duarte GM,Tomazini MV,Oliveira A,Moreira L,Tocchet F,Worschech A,Torresan RZ

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:Clearance of large molecules from the interstitial space is an important function of lymphatics and is affected by local pathologic changes. OBJECTIVE:To determine if the clearance rate of interstitially injected albumin is correlated to tumour characteristics and outcome in women with invasive breast cance...

journal_title：Breast cancer research and treatment

authors： Sterns EE,SenGupta S,Zee B

更新日期：1997-01-01 00:00:00

abstract：:Breast cancer has emerged as the most frequent malignancy among Korean women. Its clinical features have become closer to those now observed in Western countries. We performed this study to evaluate the chronological changes in Korean breast cancer characteristics and reproductive factors from 1996 to 2004. A nationwi...

journal_title：Breast cancer research and treatment

authors： Ahn SH,Yoo KY,Korean Breast Cancer Society.

更新日期：2006-09-01 00:00:00

abstract：:A model for a more precise prognosis of the risk of relapse is needed to avoid overtreatment of lymph node-negative breast cancer patients. A large derivation data set (n = 684) was generated by pooling three independent breast cancer expression microarray data sets. Two major prognostic factors, proliferation and imm...

journal_title：Breast cancer research and treatment

authors： Oh E,Choi YL,Park T,Lee S,Nam SJ,Shin YK

更新日期：2012-04-01 00:00:00

abstract：:Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women in...

journal_title：Breast cancer research and treatment

authors： Henry NL,Rae JM,Li L,Azzouz F,Skaar TC,Desta Z,Sikora MJ,Philips S,Nguyen AT,Storniolo AM,Hayes DF,Flockhart DA,Stearns V,Consortium on Breast Cancer Pharmacogenomics Investigators.

更新日期：2009-10-01 00:00:00

abstract：:Germline mutations in BRCA1/2 confer a high risk of breast cancer (BC), but the magnitude of this risk varies according to various factors. Although controversial, there are data to support the hypothesis of allelic-risk heterogeneity. We assessed variation in BC risk according to the location of mutations recorded in...

journal_title：Breast cancer research and treatment

authors： Lecarpentier J,Noguès C,Mouret-Fourme E,Stoppa-Lyonnet D,Lasset C,Caron O,Fricker JP,Gladieff L,Faivre L,Sobol H,Gesta P,Frenay M,Luporsi E,Coupier I,GENEPSO.,Lidereau R,Andrieu N

更新日期：2011-12-01 00:00:00

abstract：:Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

journal_title：Breast cancer research and treatment

authors： Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

更新日期：2016-04-01 00:00:00

abstract：PURPOSE:Immunotherapy has recently been shown to improve outcomes for advanced PD-L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA approval of the first immune checkpoint inhibitor in combination with taxane chemotherapy. To further develop predictive biomarkers and improve the...

journal_title：Breast cancer research and treatment

authors： Deng J,Thennavan A,Shah S,Bagdatlioglu E,Klar N,Heguy A,Marier C,Meyn P,Zhang Y,Labbe K,Almonte C,Krogsgaard M,Perou CM,Wong KK,Adams S

更新日期：2021-01-01 00:00:00

abstract：:Nipple-sparing mastectomy (NSM) provides a cosmetic and psychological benefit for patients, but concerns on nipple involvement (NI) of tumor continue to persist. Several studies have reported factors for predicting NI, but the results were inconsistent and uncomprehensive, making patient selection difficult. The aim o...

journal_title：Breast cancer research and treatment

authors： Zhang H,Li Y,Moran MS,Haffty BG,Yang Q

更新日期：2015-06-01 00:00:00

abstract：:We investigated the expression of -CXC chemokine ligand 13 (CXCL13) and its receptor -CXC chemokine receptor 5 (CXCR5) in 98 breast cancer (BC) patients with infiltrating duct carcinoma, out of which 56 were found lymph node metastasis (LNM) positive. Interestingly, co-expression of CXCL13 and CXCR5 showed a significa...

journal_title：Breast cancer research and treatment

authors： Biswas S,Sengupta S,Roy Chowdhury S,Jana S,Mandal G,Mandal PK,Saha N,Malhotra V,Gupta A,Kuprash DV,Bhattacharyya A

更新日期：2014-01-01 00:00:00

abstract：:Review of comparative pathology studies of breast cancer among Japanese women and other ethnic groups reveals consistent differences in tumor morphology and host response. Japanese women show lower rates of breast cancer than Caucasian women, a difference that is accounted for by increased rates of this cancer in post...

journal_title：Breast cancer research and treatment

authors： Stemmermann GN

更新日期：1991-05-01 00:00:00

abstract：PURPOSE:Chemotherapy-induced amenorrhea (CIA) by newer taxane-containing regimens was evaluated in early breast cancer (EBC) patients. METHODS:A prospective cohort of 122 premenopausal EBC patients participated in a phase III trial of preoperative docetaxel/capecitabine (TX) versus doxorubicin/cyclophosphamide (AC); 3...

journal_title：Breast cancer research and treatment

authors： Han HS,Ro J,Lee KS,Nam BH,Seo JA,Lee DH,Lee H,Lee ES,Kang HS,Kim SW

更新日期：2009-05-01 00:00:00

abstract：PURPOSE:Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood...

journal_title：Breast cancer research and treatment

authors： Janssen N,Fortis SP,Speigl L,Haritos C,Sotiriadou NN,Sofopoulos M,Arnogiannaki N,Stavropoulos-Giokas C,Dinou A,Perez S,Pawelec G,Baxevanis CN,Shipp C

更新日期：2017-01-01 00:00:00

abstract：:Expression of HOX transcript antisense intergenic RNA (HOTAIR)--a long non-coding RNA--has been examined in a variety of human cancers, and overexpression of HOTAIR is correlated with poor survival among breast, colon, and liver cancer patients. In this retrospective study, we examine HOTAIR expression in 164 primary ...

journal_title：Breast cancer research and treatment

authors： Sørensen KP,Thomassen M,Tan Q,Bak M,Cold S,Burton M,Larsen MJ,Kruse TA

更新日期：2013-12-01 00:00:00

abstract：PURPOSE:TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. METHODS:A total of 11,393 TNBC patients who had bet...

journal_title：Breast cancer research and treatment

authors： Bae SY,Nam SJ,Jung Y,Lee SB,Park BW,Lim W,Jung SH,Yang HW,Jung SP

更新日期：2018-11-01 00:00:00

abstract：:Mutations in the BRCA1 and BRCA2 genes account for the majority of hereditary breast ovarian cancer (HBOC) cases. However, after BRCA1 and BRCA2 screening still the most HBOC cases remain negative for any mutational event. Accordingly, in these cases raises the relevance to analyze the unusual BRCA1/2 variants of unce...

journal_title：Breast cancer research and treatment

authors： Konecny M,Vizvaryova M,Zavodna K,Behulova R,Gerykova Bujalkova M,Krivulcik T,Cisarik F,Kausitz J,Weismanova E

更新日期：2010-01-01 00:00:00

abstract：:The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

journal_title：Breast cancer research and treatment

authors： Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

更新日期：2009-05-01 00:00:00